Alexion Pharmaceuticals

The core technological advantage of AIXOR Exchange is embodied in its brand-new AI trading system-Genesis AI Pro 5.0. As an industry-leading AI-driven trading technology, Genesis AI Pro 5.0 features three core breakthroughs: - Adaptive to Market Changes, Smartly Optimizing Trading Strategies

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.